Literature DB >> 16802838

NICE says no to inhaled insulin: what lessons should we learn?

Nick Freemantle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16802838     DOI： 10.2165/00019053-200624070-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  5 in total

1.  Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes.

Authors:  Nick Freemantle; Lawrence Blonde; Didier Duhot; Marcus Hompesch; Robert Eggertsen; F D Richard Hobbs; Luc Martinez; Stuart Ross; Björn Bolinder; Elmar Stridde
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

2.  Real-world trials to answer real-world questions.

Authors:  Nick Freemantle; Lawrence Blonde; Bjorn Bolinder; Robert A Gerber; F D Richard Hobbs; Luc Martinez; Stuart Ross
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model.

Authors:  Elvira Mueller; Stefanie Maxion-Bergemann; Dmitry Gultyaev; Stefan Walzer; Nick Freemantle; Chantal Mathieu; Bjorn Bolinder; Robert Gerber; Marion Kvasz; Rito Bergemann
Journal:  Diabetes Technol Ther       Date:  2006-04       Impact factor: 6.118

4.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

5.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321
  5 in total
  1 in total

1.  Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens.

Authors:  Jeremy Chancellor; Samuel Aballéa; Alison Lawrence; Rob Sheldon; Sandrine Cure; Juliette Plun-Favreau; Nick Marchant
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.